Market Overview

Arizona Bioscience Community to Honor Dr. Michael E Berens of TGen for Leadership

Share:

The Arizona Bioindustry Association (AZBio)
today announced today that Michael E. Berens, PhD, Professor; Deputy
Director for Research Resources; and Director of the Cancer and Cell
Biology Division at the Translational Genomics Research Institute (TGen)
is the Jon W. McGarity Arizona Bioscience Leader of the Year. Dr. Berens
will be honored by Arizona's bioscience and business communities for his
leadership and his contributions to building the coalitions that have
shaped the state's life science industry at the 2018 AZBio Awards on
October 3, 2018 at the Phoenix Convention Center.

Dr. Berens has relentlessly pursued collaborations that have led to the
expansion of Arizona's bioscience infrastructure.

Under the leadership of Bob Case and Dr. Berens, the Arizona Bioindustry
Cluster was born in 1997. While at the Barrow Neurological Institute,
Dr. Berens was the first to lead the cluster and for over 20 years has
been a leading voice in Arizona's bioscience community.

Early on, he was a catalyst, sparking the interest of Arizona's
politicians and industry leaders and encouraging them to gather the
resources and make the investments needed bring TGen to Arizona and
begin what would become the Phoenix Biomedical Campus.

He continues to be active in the technology and public policy sectors
and is a past member of the AZBio Board of Directors and past Chairman
of the Arizona Technology Council.

In everything he does, Dr. Berens embraces a collaborative approach to
his outreach with research, public/private partnerships, health care
providers and individuals to promote not only the advancement of the bio
science space, but Arizona's leadership role as well.

He mentors and guides students and young researchers and has long served
as a "go-to" resource for Arizona's business leaders.

His grasp of human nature, ability to bring people together and his
"what does a win look like?" mantra makes him an Arizona Bioscience
leader that key initiatives recruit for their teams.

"Dr. Berens was the first person to help me see the promise and
potential of Arizona's emerging bioscience industry," shared Joan
Koerber-Walker, president and CEO of AZBio. "Great leaders are great
communicators. He has spent countless hours advocating for our
community, our bioscience industry, and for the patients who will
benefit from the discoveries and innovations that translational research
can deliver. His quiet, unassuming style helps us all to put things in
perspective as he encourages us to explore new ways to get better
outcomes."

Helping patients and their families find a path to the "most best
days".

In addition to his roles as Deputy Director for Research Resources at
TGen, Dr. Berens serves as Director of the Cancer and Cell Biology
Division and Professor in the Brain Tumor Unit. The Brain Tumor Unit at
TGen studies cancers that originate in the brain and cancers that
metastasize to the brain. Specific anatomic and physiologic aspects of
the central nervous system establish unique interactions between tumor
cells and host cells, which his team pursues with the intent of bringing
new treatment approaches to these devastating diseases. Three pillars of
study dominate the landscape of the BTU's research: Invasion Biology,
Treatment Development, and Correlative Studies to Clinical Trials.

Dr. Berens received his Ph.D. from the University of Arizona. His
academic career has included appointments at the University of Zurich,
the Bowman Gray School of Medicine of Wake Forest University, the
University of California at San Francisco, and the Barrow Neurological
Institute or BNI.

At BNI, he served for 12 years as Senior Investigator and Director of
Neurology Research. He currently leads a translational research program
in brain tumors that includes preclinical therapy development, novel
treatment target discovery, and the study of malignant cell motility;
early stage clinical trials in patients with malignant glioma, informed
by genomic and proteomic profiling (theranostic biomarkers), demand
major portions of his attention. His research program includes
collaborations with Barrow Neurological Institute, Mayo Clinic,
multi-institutional consortia and laboratories in Seoul, Tokyo, Sydney
and Bergen (Norway). In addition, he serves on editorial boards for
scientific journals and committees that support governmental agencies,
professional societies, and non-profit organizations. Dr. Berens current
research is funded by the National Institutes of Health and private
medical Foundations, including the Ben & Catherine Ivy Foundation. He
holds four patents, and founded two for-profit ventures: Creative
Scientific Methods Inc., and Avolix Pharmaceuticals, Inc.

For his leadership in the scientific community, the Arizona Bioscience
Community and his unswerving commitment to building collaborative
solutions that continue to move our community forward year after year,
Dr. Michael E. Berens is the 2018 Jon W. McGarity Arizona Bioscience
Leader of the Year.

A key component of Arizona
Bioscience Week
, The AZBio Awards & Life Science Fiesta brings
together Arizona's life science and leadership community with visitors
from around the country to celebrate life-science innovation and
innovators. The AZBio
Awards
takes place on the evening of October 3, 2018 at the Phoenix
Convention Center. Highlights of the evening will include honoring Dr.
Daniel D. Von Hoff with the AZBio Pioneer Award for Lifetime Achievement
and a celebration of the achievements of leading researchers, educators,
and innovator companies. The Life Science Fiesta following the award
ceremony features a Student Discovery Zone that showcases the work of
fifty students from Arizona high schools, community colleges, and
universities along with exhibits featuring Arizona companies and patient
advocacy organizations. The AZBio Awards & Life Science Fiesta are
presented by AZBio and the Arizona
Commerce Authority
.

The White Hat Life Science Investor Conference (White
Hat 2018
) brings together the next generation of biotech and
healthcare pioneers from across the Rocky Mountain Southwest Region with
investors locally, nationally, and internationally. Held at the Phoenix
Convention Center on October 4, 2018, White Hat 2018 is a collaboration
between the bioscience industry associations across the region. The
conference showcases investment opportunities for investment into
privately-held companies in the areas of diagnostics, therapeutics,
medical devices, and health information technology. Thirty-two companies
have been competitively selected by a committee of experienced life
science investors to present at White Hat 2018. Companies that presented
at White Hat in 2014 and 2016 have gone on to receive almost $200
million in investment from private investors and corporate investors.

For more information on Arizona Bioscience Week, visit www.AZBio.org/AZBW2018.

For more information on the 2018 AZBio Awards, visit www.AZBioAwards.com

For more information about White Hat 2018, visit www.WhiteHatInvestors.com.

About AZBio

For 15 years, the Arizona Bioindustry Association (AZBio) has supported
life science innovation and life science innovators in Arizona. A key
component in Arizona's life science ecosystem, AZBio is the only
statewide organization exclusively focused on Arizona's bioscience
industry. AZBio membership includes patient advocacy organizations, life
science innovators, educators, healthcare partners and leading business
organizations. AZBio is the statewide affiliate of the Biotechnology
Innovation Organization (BIO) and works in partnership with AdvaMed,
MDMA, and PhRMA to advance innovation and to ensure that the value
delivered from life-changing and life-saving innovation benefits people
in Arizona and around the world.

For more information visit www.AZBio.org
and www.AZBio.TV

View Comments and Join the Discussion!
 
Fastest news service for the smartest traders
$147 Free 14 day Trial